Drapeau France                     Drapeau espagne                    Drapeau UK                  drapeau américain             drapeau émirats

Life expectancy in the US in 2020

The Menopause Troubles Solution



The androgenic disease of menopause

If there is no symptom, there is no disease. If there is no disease no curative treatment is necessary.

Is there a disease behind the word of menopause ?

Errors in menopause treatment.

Treatment of this disease is done by mesterolone that replaces testosterone and dihydrotestosterone when it is necessary (the deficit being demonstrated by blood tests).

The concept and pathology of "menopausal disease" has never been described before. The reality of this pathological entity is founded:

1. on knowledge of the physiology and hormonal biochemistry of the female cycle, found in the excellent hormonology treatises (see: Baulieu E-E. and Kelly Paul A. Hormones, Hermann publishers, 1990).

2. on clinical experience and detailed biochemical analyzes that began in 1998 in "postmenopausal" women with  characteristic symptoms of "menopausal disease". The initial clinical study was pursued by an appropriate therapeutic attitude when the "menopausal disease" is diagnosed biochemically.

3. on the clinical and biological study of women who have been treated with mesterolone and who have been relieved of their symptoms.

4. each biological study here concerns the biochemical and clinical singularity of each woman.

5. The word "menopause" is limited to the cessation of menstruation. Therefore, "therapeutics of this word" do not relate to a disease an doesn't need a treatment.

6. Consequently, countless publications, "double blind studies without medically proven results, published by highly qualified specialists", "various treatments", "varied herbs", "explanations and unfounded treatments", "unnecessary hormonal replacements of all kinds (HRT) "(HRT = Estrogen and Progestin and their derivatives that cause disasters - see warning from the NHI in the USA: Important Warning), "books" using the word "menopause" (more than 28,000,000 references on google!) are not concerned with the "menopause disease" presented for the first time before a meeting of doctors in October 2015 and published in Approaches to aging control : 19:17-24,October 2015.

7. The terminology "menopause disease" corresponds in linguistics to a terminological use of collocations. I have not found any better, since the principal but non-pathological symptom of this disease is the permanent absence of periods; the pathological symptoms are listed below. I would not mind that an "enlightened mind" proposes a better definition of this disease. Those who want to improve the concept will be welcome.

8. The time has come to place the family doctor at the center of therapeutics for "menopause disease".

The menopause disease .pdf  Octobre 2015.    SEMAL Madrid

G. Debled. The menopause disease. Approaches to aging control : 19:17-24,October 2015

To understand this disease of ageing it is advisable to establish a precise definition of it. Georges Debled MD.  propounds the following definition:


The menopause disease is

the whole of physiopathological and psychopathological modifications

brought out by acute or progressive stop of ovarian production of androgens

after definitive stop of menstruations.


"Menopause disease" is a collocation. In corpus linguistics, a collocation is a sequence of words or terms that co-occur more often than would be expected by chance : "menopause disease" has a technical signification as it is a disease.

Utilized separately, menopause signifies the "stop of menstruations" and disease signifies  the "deterioration of health".


The ovaries secrete estradiol, progesterone and testosterone.

The cessation of estradiol and progesterone are linked with the stop of ovulation

 and of menstrual hemorrhages which are physiological changes.

The drastic reduction in the secretion of androgens hormones by the ovaries (at an age where the production of androgens by the suprarenal glands is already decreased) is generally not taken into account and brings about the menopause disease.

Blood rates of ovarian hormones in woman before menopause.

 The ovaries secrete estradiol, progesterone and testosterone.

The secretions of these three hormones stop in the ovaries at the time of the menopause.

The secretory and proliferative cycle controlled by estradiol and progesterone intended to fertilize ovules does not exist any more after the “suspension of the menses”. One can logically wonder which reason would justify a systematic replacement of these hormones except the fact of wanting to prolong in time an ovarian cycle become useless in the absence of ovulation?  

The total production of testosterone during a menstrual cycle is more important in quantity compared with the production of estradiol.

Consequently one is in right to ask for why estradiol substitution was proposed in the past by neglecting the production of testosterone?

The sharp fall of front testosterone secretion at the time and after the stop of menses is responsible for most of the disorders caused by the menopause disease.


The reduction in androgens’ production causes in woman to different degree:

·         functional  symptoms : hot flashes, irritability, intestinal distension, swollen legs.

·         local consequences :

o   sclerosis of bladder neck (chronic cystitis, incontinence, urgencies)

o   sclerosis of vulva (painful or difficult copulation).

·         general consequences  :

o   lipids’ disorders

o   vascular disorders

o   weakness

o    hyper coagulation

o   venous thrombosis

o   rheumatic problems

o    nervous breakdown

o   cerebral involution

o   Alzheimer’s disease

These consequences are wrongfully allotted to the lack of estradiol and progesterone (a polluted concept) whereas in fact they are the consequences of a lack of male hormones (testosterone for general consequences and dihydrotestosterone for local genital involution).

General Symptoms are the same in man suffering from andropause disease described for the first time by Georges Debled in 1988. See: http://www.man.uk.georgesdebled.org/andropause cause book.htm and http://www.man.uk.georgesdebled.org/andropause uk.htm

Local Symptoms resulting from of masculine genitalia involutions are:

·         chronic cystitis, incontinence, urgencies.  (sclerosis of bladder neck)

·          painful or difficult copulation ( sclerosis of vulva)

and  are consequences of a lack of dihydrotestosterone production (lack of testosterone leads to a decreased production of dihydrotestosterone).

Balanced treatment with male hormones (mesterolone) is indicated in menopause disease as in andropause disease.

This fact is generally ignored so that the administration of estradiol (or estrogens) associated or not with progesterone or progestogens doesn’t constitute the treatment for the menopause disease whose I gave the definition (androgens’ deficiencies).

One can even wonder whether the “traditional” treatments of hormonal replacement therapy (HRT) do not worsen the state of good health. See http://www.whi.org                      


If there is no symptom, there is no disease. If there is no disease no curative treatment is necessary.

Orally administration of mesterolone in amounts between 5 milligrams and 25 milligrams per day constitutes the specific treatment.

Interest for the pharmaceutical industry

 1.       Today Mesterolone is not prescribed for woman and its prescription is even exclusive for male patients.

 2.             The North American Menopause Society (NAMS) defines Androgens as: “a group of hormones that promote the development and maintenance of male secondary sex characteristics and structures. They are produced in smaller quantities in women and are important in the synthesis of estrogen. They also play a role in sexual function, muscle mass and strength, bone density, distribution of fat tissue, energy, and psychological well-being. With women, the major androgens are produced in the ovaries and adrenal glands and include testosterone, androstenedione, and dehydroepiandrosterone (DHEA). Also available as prescription and nonprescription therapies, but not government approved for use in women”.

Mesterolone administration is prohibited for woman by the manufacturers because of risks of virilisation as opposed to what this description shows with physiological doses.

Mesterolone covers all indications for androgens with women

3.   It is here question to industrialize mesterolone at very another end that for which it was intended by manufacturing tablets of 5 and 10 milligrams sectile in two parts what makes it possible to cover a large range of therapeutic amounts.

4.   Mesterolone is a hormone prescribed for man to compensate a lack of production of  androgens. Used for man since 1967 it is henceforth in the public domain. Its manufacturing technique is known. No harmfulness was described to date.

5.   Before menopause woman secretes each day of the cycle 0.2 milligrams of testosterone = 200 micrograms or    200,000 nanograms or 200,000,000 picograms. Mesterolone makes it possible to replace androgens whose production is strongly decreased in woman with menopause disease.

6.   The indications relate to all the therapeutic ones containing mesterolone for woman; that the mesterolone is used alone or in partnership with all the pharmaceutical compositions using estrogens alone or in partnership with progesterone or progestogens ones.

7. Mesterolone prescription is the right way to treat premenopausal problems in addition to compositions using estrogens alone or in partnership with progesterone or progestogens ones. Mesterolone balances the properties of estrogens (prescribed with or without  progestogens)  impairing and excess of actions o their hormonal targets.

8. "Traditional" compounding is not prohibited. However the interest of the industrialization for women is evident. Making also dermal patches and pills with long lasting effects.

Why is mesterolone the treatment for androgen's deficiencies in woman ?

Mesterolone cannot be aromatized in estradiol (contrary to testosterone). Its methyl radical  inserted on Carbon 1 of the testosterone confers this property.

 At physiological doses Mesterolone does not influence the secretion of the pituitary gland so that the secretion of LH is not modified (contrary to testosterone).

          Mesterolone prescribed in small amounts adds its effects to those of testosterone secreted by the organism.

          With the prescribed physiological pharmacological amounts doping is impossible and the overdose too. Mesterolone is prescribed orally in amounts varying between 5 milligrams and ten milligrams per day approximately. A substitution amount of 25 milligrams per day can be considered. The secretion of LH by the pituitary gland is not inhibited (contrary to testosterone).

Mesterolone molecular structure has characteristics of dihydrotestosterone (DHT) which is directly effective on the masculine sex organs of women (clitoris, labia majora and bladder neck) and on brain tissue (preventing Alzheimer’s disease) (15).

Mesterolone can be prescribed alone.

To restore balance with the androgens Mesterolone can be associated with certain compositions containing estradiol and of progesterone (or progestogens) in cases or these treatments would justify themselves. Any woman secretes each day 0.2 milligrams of male hormones. This balance is essential to the good performance of the hormonal targets. It is most probably this lack of balance by default of androgens which explains the disasters revealed by the “WOMENS' HEALTH INITIATIVE” in addition to inadequate diagnosis and treatments whith estradiol and progestogens. http://www.whi.org             

Non-existent risks of virilism with mesterolone treatment

The treatment of androgen’s deficiency simply consists in replacing missing secretions of testosterone (and dihydrotestosterone) thanks to mesterolone properties.  In this case the woman finds simply her former physiological state and prevents the disastrous consequences described above. Mesterolone used in small amounts allows that.

 Virilism secondary to an excessive administration of mesterolone is the consequence of a doping which must be avoided in all cases. Virilism doesn’t exist at physiological doses

Androgen's scientific biological deficit - Diagnosis background

About determination of testosterone  and dihydrotestosterone in serum :

  • The GC-MS (Gaz Chromatography- Mass Spectrometry) is the most precise method (Taieb and all, 2003) (8)

  • Direct RIA studies are significant  (ACS 180 from Bayer Diagnostics) (Davison SL and all. 2005 ) (9)

  • Androgen glucuronides, instead of testosterone, are interesting markers of androgenic activity in women (Labrie F. and all.2006) (10).

In the Georges Debled’s study the scientific biological diagnosis of androgen’s deficiencies is made on the total “pool” of androgens (RIA) in men since 40 years and in women since 13 years concluding that the level of androgens’ daily production is a key diagnosis (see below).This method led Georges Debled MD. to the concept of andropause disease (which is different from hypogonadism) which treatment is made with mesterolone (See: www.man.uk.georgesdebled.org/andropause uk.htm)

The 10 years’ study on androgens’ deficiencies in women is founded on RIA analyses made by a reference laboratory (Liège University, CHU, Liège, Belgium)

The Georges Debled’s androgens’ pool study reflects the daily production of androgens:

Androgens in serum (RIA)

·         Total testosterone

·         Dihydrotestosterone                 

·         Androstanediol glucuronide

·         (Androsterone glycuronide)


·         DHEA

·         DHEA Sulfate

·         Δ4-Androstènedione

Metabolites in urine over 24 hours

  • Total 17 ketosteroids
  • Complete Chromatography of 17 ketosteroids
  • Androstanediol glucuronide

FSH, LH and estradiol in serum

Clinical background

If there is no symptom there is no disease. And if there is no disease no treatment is necessary.

The Georges Debled’s study concludes that symptoms of androgens’ deficiencies in women are correlated with a low daily production of androgens reflected by low serum androgens’ levels and low levels of metabolites in serum and urine over 24 hours (the androgens’ pool study) leading to treat those women successfully with mesterolone since 13 years with spectacular results and without any side effect.

The global androgens’ pool was evaluated for research purpose. A simplified biological diagnosis is often enough in general practice

More than 50 women are followed since 13 years. Our 13 years experience with mesterolone prescription for androgen’s deficit in general practice will continue as an increased number of women ask to follow this treatment. Hormonal substitution is founded on the clinical story and on a simplified hormonal and biological check up (which is not expensive) for each case individually (11).

 General practitioners and Gynecologists will be now aware of androgens' deficit in woman

Each general practitioner, each gynecologist, each doctor will be aware of:

·         The clinical diagnosis of androgens’ deficiencies in women.

·         The simplified and non expensive biological diagnosis of androgens’ deficiencies in women.

·         The successful and cheap treatment of androgens’ deficiencies in women with mesterolone.

The Georges DEBLED’s study on menopause disease is a new medical concept

·         It was not possible to publish those conclusions before because consequences of  menopause  were wrongfully allotted to the lack of oestradiol and progesterone.

This polluted concept is still considered as a “dogma” by doctors in general.


·         Even more import and prescription of mesterolone are not permitted by the US government.


·         Manufacturers reserved mesterolone only for men.


·         The study was conducted  by Georges Debled MD. during the last ten years after the first conclusions of the WHI study in 2002. JAMA. 2002 Jul 17;288(3):321-33(5)


·         This confidential study was possible in Europe where mesterolone is available.


·         After the conclusions of the WHI study to date and the recent judgment (June 2011) of the U.S. Supreme Court (17) Georges Debled MD.discloses here for the first time the conclusions of his study on mesterolone treatment  for androgens’ deficiencies in woman which is the real solution in the world for women with androgens’ deficiencies before and after menopause .This study has not been published in a scientific revue nor in a magazine. It has not been presented in any medical congress or conference.


·         It is an absolute new concept (18)

Future investigations

With the help of governments and of manufacturers exhaustive studies will be made to specify contours of mesterolone as treatment for androgens’ deficiencies in women.

These future studies on large scale will be conducted within the general framework of biology of ageing.

see bibliography